Valuation: PolyPid Ltd.

Market Cap 106M 94.22M 87.78M 79.89M 150M 10.17B 152M 1.06B 413M 5.19B 397M 388M 16.69B P/E 2026 *
-5.84x
P/E 2027 * -4.24x
Enterprise Value 106M 94.22M 87.78M 79.89M 150M 10.17B 152M 1.06B 413M 5.19B 397M 388M 16.69B EV / Sales 2026 *
7.04x
EV / Sales 2027 * 12.2x
Free-Float
87.66%
Yield 2026 *
-
Yield 2027 * -
1 day+0.19%
1 week-2.07%
Current month-1.33%
1 month-3.53%
3 months+3.59%
6 months+18.45%
Current year+19.82%
1 week 5.03
Extreme 5.03
5.55
1 month 5
Extreme 5
5.56
Current year 3.65
Extreme 3.65
5.73
1 year 3.06
Extreme 3.06
5.73
3 years 2.3
Extreme 2.3
9.2
5 years 2.3
Extreme 2.3
257.1
10 years 2.3
Extreme 2.3
583.5
Manager TitleAgeSince
Chief Executive Officer 52 30/06/2022
Director of Finance/CFO 39 -
Chief Tech/Sci/R&D Officer 61 17/08/2025
Director TitleAgeSince
Director/Board Member 84 31/03/2008
Director/Board Member 52 07/08/2022
Director/Board Member 74 30/11/2018
Date Insider Type Main position Quantity % Market Cap. Importance
15/07/26 Free

Director

9,132 0.0896%
15/07/26 Free

Director

9,132 0.0896%
15/07/26 Free

Chairman

9,132 0.0896%
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%-2.07%+48.57%+38.67% 106M
+0.02%-3.52%+36.11%+111.11% 1,019B
-1.21%-6.99%+34.08%+60.96% 610B
+1.12%-0.20%+13.62%+80.24% 470B
-3.30%-6.15%+56.45%+34.69% 344B
+0.93%-1.83%+21.65%+41.43% 336B
+0.12%-4.05%+10.70%+33.53% 266B
-0.89%-5.83%-7.00%+7.91% 241B
-0.01%-3.62%+35.28%+52.02% 218B
-0.08%-4.98%+28.34%+93.61% 179B
Average +0.21%-3.47%+27.78%+55.42% 368.29B
Weighted average by Cap. +0.45%-3.51%+28.40%+68.66%

Financials

2026 *2027 *
Net sales 15M 13.38M 12.47M 11.35M 21.37M 1.44B 21.52M 151M 58.61M 737M 56.31M 55.1M 2.37B 8.68M 7.74M 7.21M 6.56M 12.36M 835M 12.45M 87.12M 33.89M 426M 32.57M 31.86M 1.37B
Net income -20.03M -17.87M -16.64M -15.15M -28.52M -1.93B -28.74M -201M -78.25M -984M -75.18M -73.56M -3.16B -31.55M -28.15M -26.22M -23.86M -44.94M -3.04B -45.27M -317M -123M -1.55B -118M -116M -4.98B
Net Debt - -
Logo PolyPid Ltd.
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Employees
72
Date Price Change Volume
05/10/26 US$5.200 +0.19% 102,016
02/10/26 US$5.190 -3.35% 168,309
01/10/26 US$5.370 +1.90% 118,780
30/09/26 US$5.270 -0.38% 47,391
29/09/26 US$5.290 -0.38% 66,038
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.200USD
Average target price
11.75USD
Spread / Average Target
+125.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PYPD Stock